MYGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Myriad Genetics Inc (MYGN) is not a strong buy for a beginner, long-term investor at this time. The company's financial performance shows significant declines in revenue, net income, and EPS. Analysts have lowered their price targets, and there are no clear positive catalysts or strong trading signals to suggest immediate upside potential. The technical indicators are neutral, and options data suggests bearish sentiment. Given the lack of compelling reasons to invest now, it is better to hold off on buying this stock.
The MACD is positive but contracting, suggesting weakening momentum. RSI is neutral at 43.708, and moving averages are converging, indicating no clear trend. Key support and resistance levels are at S1: 4.615 and R1: 5.383, with the stock trading near support levels. Overall, the technical indicators are neutral.
No recent news or significant positive catalysts. Analysts note potential pipeline catalysts in 2026, but these are speculative and long-term.
Significant declines in financial performance, including revenue (-0.38% YoY), net income (-81.41% YoY), and EPS (-82.98% YoY). Analysts have lowered price targets, and there is no recent insider or hedge fund buying activity.
In Q4 2025, revenue dropped to $209.8M (-0.38% YoY), net income dropped to -$7.9M (-81.41% YoY), and EPS dropped to -$0.08 (-82.98% YoY). Gross margin also declined to 69.97% (-2.34% YoY), indicating worsening profitability.
Analysts have lowered price targets recently: UBS to $6 (from $8), Wells Fargo to $6 (from $6.50), and TD Cowen to $7 (from $9). Ratings remain Neutral or Hold, reflecting a cautious stance on the stock.
